News

Paediatric cancer, innovating today for better treatment tomorrow

More cures and better cures. With the dual purpose of improving survival and reducing sequelae, Gustave Roussy is contributing to ambitious research programmes in Paediatric Oncology and to the management of young adults.

Published on

Changed on

Journée Internationale des Cancers de l'Enfant

More cures and better cures. With the dual purpose of improving survival and reducing sequelae, Gustave Roussy is contributing to ambitious research programmes in Paediatric Oncology and to the management of young adults.

Two novel trials devoted to children and adolescents

Today, less than 10% of young patients in Europe in relapse have access to a new drug. For Professor Vassal, Director of Clinical Research, “The issue is to speed up access to novel treatments for children and adolescents with treatment failure.” To achieve this, the Institute is embarking on two new clinical trials. Since late December 2015, MAPPYACTS has been  determining the molecular portrait of 300 young  patients. The ImmunoACTS study is integrated with this project and seeks to characterize the immune cells which are present. The long-term objective is to develop bespoke drugs able to block the immune cells which are responsible for the observed resistance to treatment. The Acsé-eSMART trial, which will commence shortly,  will  test several novel agents in 250 children. It is hoped over 2 years to double the number of new drugs tailored to the defined molecular portraits.

A long-term follow-up clinic

Whereas progress in recent decades means that 80% of young patients can be cured, almost 2/3 of them run the risk of sequelae. Assessing in adult life the consequences of treatments administered to patients in childhood is also a way of improving the management of children who are being treated today. Gustave Roussy has, therefore, established a Long-Term Follow-up Clinic to inform patients and to detect and treat late complications in adults whose childhood cancer was cured.

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin